Bristol-Myers Squibb Company / Halozyme Therapeutics, Inc.

Immuno-Oncology (Subcutaneous Administration)

Disease Overview

ENHANZE is a drug-delivery platform built on recombinant human hyaluronidase (rHuPH20) that transiently degrades subcutaneous hyaluronan, enabling large-volume SC delivery of biologics that would otherwise require IV infusion. The technology addresses a system-wide pain point in immuno-oncology: chair-time, infusion-suite capacity, and patient convenience for chronically administered checkpoint inhibitors.

Competitive Landscape

When BMS signed in September 2017, Halozyme's ENHANZE was already validated by Roche's SC Herceptin, SC MabThera, and SC Hyqvia (Takeda IG)—and Roche concurrently extended its own ENHANZE deal in 2017. The 2017 BMS-Halozyme alliance covered up to 11 immuno-oncology targets including PD-1 (nivolumab), positioning BMS to defend Opdivo against Merck's Keytruda, which was also pursuing SC formulation via its in-house effort with Alteogen (announced 2020). Direct competitors to ENHANZE included Alteogen's Hybrozyme (used by Merck for SC pembrolizumab and by AstraZeneca), and Halozyme's own competitive moat via patent estate around rHuPH20. The deal mattered because SC PD-1 reformulation defends against biosimilars and IRA price negotiation by extending lifecycle and improving the patient/provider experience. The thesis materialized: FDA approved Opdivo Qvantig (SC nivolumab + ENHANZE) in December 2024, the first and only SC PD-1 inhibitor, with EU approval following in 2025. Halozyme more than doubled 2017 revenue guidance after the BMS+Roche deals were announced, validating the deal-time market reaction.